Case reports have documented responses to targeted therapies in urachal carcinoma, including EGFR inhibitors (gefitinib, cetuximab), VEGFR inhibitors (sunitinib), and PARP/MEK inhibitors (17–21). Here, MAP2K7 is linked to bladder urachal carcinoma.